KR20230096959A - Il-10을 포함하는 이중 시토카인 융합 단백질 - Google Patents

Il-10을 포함하는 이중 시토카인 융합 단백질 Download PDF

Info

Publication number
KR20230096959A
KR20230096959A KR1020237005848A KR20237005848A KR20230096959A KR 20230096959 A KR20230096959 A KR 20230096959A KR 1020237005848 A KR1020237005848 A KR 1020237005848A KR 20237005848 A KR20237005848 A KR 20237005848A KR 20230096959 A KR20230096959 A KR 20230096959A
Authority
KR
South Korea
Prior art keywords
leu
ser
gly
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005848A
Other languages
English (en)
Korean (ko)
Inventor
존 멈
Original Assignee
데카 바이오사이언시즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데카 바이오사이언시즈, 인크. filed Critical 데카 바이오사이언시즈, 인크.
Publication of KR20230096959A publication Critical patent/KR20230096959A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237005848A 2020-07-20 2020-12-02 Il-10을 포함하는 이중 시토카인 융합 단백질 Pending KR20230096959A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063054208P 2020-07-20 2020-07-20
US63/054,208 2020-07-20
PCT/US2020/062907 WO2022019945A1 (en) 2020-07-20 2020-12-02 Dual cytokine fusion proteins comprising il-10

Publications (1)

Publication Number Publication Date
KR20230096959A true KR20230096959A (ko) 2023-06-30

Family

ID=79291996

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005848A Pending KR20230096959A (ko) 2020-07-20 2020-12-02 Il-10을 포함하는 이중 시토카인 융합 단백질

Country Status (11)

Country Link
US (19) US11292822B2 (enExample)
EP (1) EP4181957A4 (enExample)
JP (1) JP2023534847A (enExample)
KR (1) KR20230096959A (enExample)
CN (1) CN116322785A (enExample)
AU (1) AU2020459746A1 (enExample)
BR (1) BR112023001187A2 (enExample)
CA (1) CA3186753A1 (enExample)
IL (1) IL300062A (enExample)
MX (1) MX2023000948A (enExample)
WO (1) WO2022019945A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025110822A1 (ko) * 2023-11-24 2025-05-30 주식회사 메드팩토 피브로넥틴 엑스트라도메인 b (extradomain b of fibronectin, edb-fn) 및 전환성장인자 베타(transforming growth factor β, tgfβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212598A1 (en) 2019-04-19 2020-10-22 Synerkine Pharma B.V. A fusion protein comprising il13
CA3186753A1 (en) * 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
US20230210953A1 (en) * 2021-12-16 2023-07-06 Deka Biosciences, Inc. Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer
CA3244604A1 (en) * 2022-02-22 2023-08-31 Deka Biosciences, Inc. METHOD FOR REDUCING A BISPECIFIC T LYMPHOCYTE RECRUITER OR A CHIMERICAL ANTIGEN RECEPTOR T LYMPHOCYTE CYTOKINE RELEASE SYNDROME USING INTERLEUKIN 4 OR 10, OR AN ASSOCIATED FUSION PROTEIN
WO2025148750A1 (zh) * 2024-01-08 2025-07-17 上药生物治疗（香港）有限公司 膜表达il-10及其用途
CN119954974B (zh) * 2025-04-09 2025-07-22 四川康德赛医疗科技有限公司 一种工程化巨噬细胞，其制备方法及抗纤维化的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
CA2648484A1 (en) 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
EP2091568A2 (en) 2006-10-31 2009-08-26 East Carolina University Fusion proteins comprising a anti-inflammatory cytokine and an antigen for treatment of immune disorders
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
DK3281952T3 (da) 2007-10-30 2020-08-03 Philogen Spa Antigen, der er forbundet med reumatoid artritis
NO2344540T3 (enExample) 2008-10-02 2018-04-28
CA2800488A1 (en) * 2010-05-26 2011-12-01 Regents Of The University Of Minnesota Single-chain variable fragment anti-cd133 antibodies and uses thereof
WO2012045334A1 (en) 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2872964T3 (es) 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
JP6333730B2 (ja) 2011-12-12 2018-05-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法
EP2820033A1 (en) 2012-02-29 2015-01-07 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
PE20150645A1 (es) 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
ES2743423T3 (es) * 2012-10-03 2020-02-19 Philogen Spa Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
PE20151893A1 (es) 2013-03-14 2015-12-30 Parkash Gill Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
CA2910044A1 (en) 2013-04-26 2014-10-30 Philogen S.P.A. Il4 conjugated to antibodies against extracellular matrix components
WO2015117930A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
WO2015175957A1 (en) 2014-05-16 2015-11-19 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
KR101811050B1 (ko) 2015-09-02 2017-12-21 경북대학교 산학협력단 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물
WO2017091611A1 (en) 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
RU2018124307A (ru) 2015-12-04 2020-01-14 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
US20190125840A1 (en) 2016-04-12 2019-05-02 Philogen S.P.A. Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US20200306375A1 (en) 2017-02-22 2020-10-01 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
US11939385B2 (en) * 2017-05-16 2024-03-26 ALX Oncology Inc. Activatable antibodies and methods of use thereof
WO2019201866A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Fusion protein
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
CN121652287A (zh) * 2019-03-06 2026-03-13 德卡生物科学公司 Il-10变体分子和治疗炎性疾病和肿瘤的方法
EP4087947A4 (en) * 2020-01-09 2024-05-01 Deka Biosciences, Inc. METHODS OF USING GENETIC MARKERS, SNPS AND/OR INDELS TO DETERMINE SENSITIVITY TO IL-10 TREATMENT
CN115867275A (zh) 2020-04-13 2023-03-28 大学健康网络 治疗细胞因子释放综合征的方法
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
CA3215528A1 (en) 2021-05-11 2022-11-17 Salvatore Albani Chimeric antigen receptors and modified cells comprising the same
WO2023114775A2 (en) 2021-12-13 2023-06-22 Deka Biosciences, Inc. Dual cytokine fusion proteins comprising multi-subunit cytokines
US20230210953A1 (en) 2021-12-16 2023-07-06 Deka Biosciences, Inc. Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer
CA3244604A1 (en) 2022-02-22 2023-08-31 Deka Biosciences, Inc. METHOD FOR REDUCING A BISPECIFIC T LYMPHOCYTE RECRUITER OR A CHIMERICAL ANTIGEN RECEPTOR T LYMPHOCYTE CYTOKINE RELEASE SYNDROME USING INTERLEUKIN 4 OR 10, OR AN ASSOCIATED FUSION PROTEIN

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025110822A1 (ko) * 2023-11-24 2025-05-30 주식회사 메드팩토 피브로넥틴 엑스트라도메인 b (extradomain b of fibronectin, edb-fn) 및 전환성장인자 베타(transforming growth factor β, tgfβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도

Also Published As

Publication number Publication date
US20240059748A1 (en) 2024-02-22
WO2022019945A1 (en) 2022-01-27
US20220017587A1 (en) 2022-01-20
US11292822B2 (en) 2022-04-05
US12116389B2 (en) 2024-10-15
US20240076339A1 (en) 2024-03-07
EP4181957A4 (en) 2024-08-07
US12116391B2 (en) 2024-10-15
US20240076338A1 (en) 2024-03-07
CN116322785A (zh) 2023-06-23
US11618775B2 (en) 2023-04-04
US20240067688A1 (en) 2024-02-29
US20250135241A1 (en) 2025-05-01
CA3186753A1 (en) 2022-01-27
US20220380428A1 (en) 2022-12-01
JP2023534847A (ja) 2023-08-14
AU2020459746A1 (en) 2023-03-16
US12122814B2 (en) 2024-10-22
US20220281935A1 (en) 2022-09-08
US20240076335A1 (en) 2024-03-07
US20220275039A1 (en) 2022-09-01
US20220275040A1 (en) 2022-09-01
US11572397B2 (en) 2023-02-07
US11613563B2 (en) 2023-03-28
US11608368B2 (en) 2023-03-21
US11629178B2 (en) 2023-04-18
MX2023000948A (es) 2023-04-14
US12145007B2 (en) 2024-11-19
US20240076337A1 (en) 2024-03-07
US20240059750A1 (en) 2024-02-22
US20220340631A1 (en) 2022-10-27
US20240067687A1 (en) 2024-02-29
US20240059749A1 (en) 2024-02-22
US12116392B2 (en) 2024-10-15
US12121755B2 (en) 2024-10-22
IL300062A (en) 2023-03-01
US20220380427A1 (en) 2022-12-01
US12263358B2 (en) 2025-04-01
US12110317B2 (en) 2024-10-08
EP4181957A1 (en) 2023-05-24
US20220267397A1 (en) 2022-08-25
US20240076336A1 (en) 2024-03-07
US12006346B2 (en) 2024-06-11
BR112023001187A2 (pt) 2023-04-04
US12116393B2 (en) 2024-10-15
US12116390B2 (en) 2024-10-15
US12268903B2 (en) 2025-04-08

Similar Documents

Publication Publication Date Title
KR20230096959A (ko) Il-10을 포함하는 이중 시토카인 융합 단백질
KR20210139312A (ko) Il-10 변이체 분자, 및 염증 질환 및 종양학의 치료 방법
KR20240156653A (ko) 다중-서브유닛 시토카인을 포함하는 이중 시토카인 융합 단백질
RU2836849C2 (ru) Вариантные молекулы il-10 и способ лечения злокачественной опухоли

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902